Three-Drug cocktail aims to shield cancer patients from dangerous transplant complication
NCT ID NCT07249346
Summary
This study is testing whether a combination of three medications given after a stem cell transplant can better prevent severe graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the patient's body. The trial will enroll 124 adults with leukemia or related blood disorders who are receiving a stem cell transplant from a donor. Researchers want to see if this drug combination helps patients survive without developing severe GVHD in the first 180 days after transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.